company background image
RDHL

RedHill Biopharma NasdaqGM:RDHL Stock Report

Last Price

US$0.50

Market Cap

US$29.3m

7D

1.2%

1Y

-88.5%

Updated

02 Oct, 2022

Data

Company Financials +
RDHL fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance0/6
Financial Health0/6
Dividends0/6

RDHL Stock Overview

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases.

RedHill Biopharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for RedHill Biopharma
Historical stock prices
Current Share PriceUS$0.50
52 Week HighUS$6.50
52 Week LowUS$0.47
Beta1.8
1 Month Change-42.02%
3 Month Change-40.29%
1 Year Change-88.50%
3 Year Change-92.74%
5 Year Change-94.76%
Change since IPO-95.47%

Recent News & Updates

Aug 17

RedHill wins EU’s orphan drug status to RHB-204 for rare lung disease

Israel-based RedHill Biopharma (NASDAQ:RDHL) announced Wednesday that the European Commission granted Orphan Drug Designation to RHB-204 as a treatment for nontuberculous mycobacteria (NTM) disease. The American depository shares of RDHL added ~5% in reaction. The decision follows a positive opinion issued by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA). Pulmonary NTM lung disease is a chronic lung disease that affects an estimated 28,000 people in the EU. The advantages of European orphan drug designation include eligibility for ten years of post-launch market exclusivity. RDHL is in talks with partners to advance RHB-204 in multiple regions. A Phase 3 trial is currently underway in the U.S. to evaluate the candidate in adults with pulmonary NTM disease caused by its leading causative agent, Mycobacterium avium complex (MAC). With its recent financials, RedHill (RDHL) said that the waning COVID impact would likely speed up the program.

Shareholder Returns

RDHLUS PharmaceuticalsUS Market
7D1.2%-0.04%-2.5%
1Y-88.5%3.2%-23.2%

Return vs Industry: RDHL underperformed the US Pharmaceuticals industry which returned 3.2% over the past year.

Return vs Market: RDHL underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is RDHL's price volatile compared to industry and market?
RDHL volatility
RDHL Average Weekly Movement12.3%
Pharmaceuticals Industry Average Movement11.3%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: RDHL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: RDHL's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2009201Dror Ben-Asherhttps://www.redhillbio.com

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study.

RedHill Biopharma Fundamentals Summary

How do RedHill Biopharma's earnings and revenue compare to its market cap?
RDHL fundamental statistics
Market CapUS$29.31m
Earnings (TTM)-US$92.02m
Revenue (TTM)US$83.42m

0.4x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RDHL income statement (TTM)
RevenueUS$83.42m
Cost of RevenueUS$38.29m
Gross ProfitUS$45.13m
Other ExpensesUS$137.15m
Earnings-US$92.02m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.58
Gross Margin54.10%
Net Profit Margin-110.31%
Debt/Equity Ratio-1,647.9%

How did RDHL perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is RDHL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RDHL?

Other financial metrics that can be useful for relative valuation.

RDHL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.1x
Enterprise Value/EBITDA-1.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does RDHL's PS Ratio compare to its peers?

RDHL PS Ratio vs Peers
The above table shows the PS ratio for RDHL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average20.9x
ACER Acer Therapeutics
62.2x227.9%US$22.4m
CURR CURE Pharmaceutical Holding
3.4xn/aUS$18.4m
INLB Item 9 Labs
1.6x21.2%US$37.6m
NTRB Nutriband
16.4x73.8%US$28.0m
RDHL RedHill Biopharma
0.4x22.8%US$29.3m

Price-To-Sales vs Peers: RDHL is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (20.9x).


Price to Earnings Ratio vs Industry

How does RDHL's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Sales vs Industry: RDHL is good value based on its Price-To-Sales Ratio (0.4x) compared to the US Pharmaceuticals industry average (2.9x)


Price to Sales Ratio vs Fair Ratio

What is RDHL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RDHL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.4x
Fair PS Ratio4.9x

Price-To-Sales vs Fair Ratio: RDHL is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (4.9x).


Share Price vs Fair Value

What is the Fair Price of RDHL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RDHL ($0.5) is trading below our estimate of fair value ($23.05)

Significantly Below Fair Value: RDHL is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Future Growth

How is RedHill Biopharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


67.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RDHL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: RDHL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RDHL is expected to become profitable in the next 3 years.

Revenue vs Market: RDHL's revenue (22.8% per year) is forecast to grow faster than the US market (7.7% per year).

High Growth Revenue: RDHL's revenue (22.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RDHL's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has RedHill Biopharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-21.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: RDHL is currently unprofitable.

Growing Profit Margin: RDHL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RDHL is unprofitable, and losses have increased over the past 5 years at a rate of 21.8% per year.

Accelerating Growth: Unable to compare RDHL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RDHL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).


Return on Equity

High ROE: RDHL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Discover strong past performing companies

Financial Health

How is RedHill Biopharma's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: RDHL has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: RDHL has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: RDHL has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: RDHL's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RDHL has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if RDHL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is RedHill Biopharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

RedHill Biopharma Dividend Yield vs Market
How does RedHill Biopharma dividend yield compare to the market?
SegmentDividend Yield
Company (RedHill Biopharma)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast in 3 Years (RedHill Biopharma)n/a

Notable Dividend: Unable to evaluate RDHL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RDHL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RDHL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RDHL's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as RDHL has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.1yrs

Average management tenure


CEO

Dror Ben-Asher (56 yo)

13.17yrs

Tenure

US$1,348,873

Compensation

Mr. Dror Ben-Asher Co-Founded at RedHill Biopharma Ltd. and has been its Chief Executive Officer since August 3, 2009. Mr. Ben-Asher serves as an Associate of Mercator Group, LLC.He has been affiliated wi...


CEO Compensation Analysis

Dror Ben-Asher's Compensation vs RedHill Biopharma Earnings
How has Dror Ben-Asher's remuneration changed compared to RedHill Biopharma's earnings?
DateTotal Comp.SalaryCompany Earnings
Mar 31 2022n/an/a

-US$92m

Dec 31 2021US$1mUS$717k

-US$98m

Sep 30 2021n/an/a

-US$98m

Mar 31 2021n/an/a

-US$82m

Dec 31 2020US$817kUS$445k

-US$76m

Sep 30 2020n/an/a

-US$64m

Jun 30 2020n/an/a

-US$55m

Mar 31 2020n/an/a

-US$50m

Dec 31 2019US$708kUS$355k

-US$42m

Sep 30 2019n/an/a

-US$38m

Jun 30 2019n/an/a

-US$39m

Mar 31 2019n/an/a

-US$39m

Dec 31 2018US$576kUS$352k

-US$39m

Sep 30 2018n/an/a

-US$42m

Jun 30 2018n/an/a

-US$47m

Mar 31 2018n/an/a

-US$47m

Dec 31 2017US$634kUS$336k

-US$46m

Sep 30 2017n/an/a

-US$43m

Jun 30 2017n/an/a

-US$37m

Mar 31 2017n/an/a

-US$32m

Dec 31 2016US$671kUS$262k

-US$29m

Sep 30 2016n/an/a

-US$28m

Jun 30 2016n/an/a

-US$22m

Mar 31 2016n/an/a

-US$22m

Dec 31 2015US$304kUS$232k

-US$21m

Compensation vs Market: Dror's total compensation ($USD1.35M) is above average for companies of similar size in the US market ($USD784.47K).

Compensation vs Earnings: Dror's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: RDHL's management team is seasoned and experienced (5.1 years average tenure).


Board Members

Experienced Board: RDHL's board of directors are considered experienced (9.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of RDHL?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,882,6853.2%
Private Companies3,928,5716.7%
Institutions6,133,40810.5%
Public Companies6,900,00111.8%
General Public39,475,12267.7%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25%.


Top Shareholders

Top 25 shareholders own 31.45% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.83%
Cosmo Pharmaceuticals N.V.
6,900,001$3.5m0%no data
6.74%
First Investments Holding Ltd
3,928,571$2.0m0%no data
3.14%
Medical Strategy GmbH, Asset Management Arm
1,830,345$919.7k3.88%0.06%
1.79%
ARK Investment Management LLC
1,045,023$525.1k21.26%no data
1.39%
Disciplined Growth Investors, Inc.
810,646$407.3k-58.43%0.01%
1.32%
Kenneth Reed
769,725$386.8k0%no data
0.86%
Shmuel Cabilly
504,327$253.4k0%no data
0.64%
Gagnon Securities LLC
375,346$188.6k2.18%0.04%
0.64%
Millennium Management LLC
372,930$187.4k0%no data
0.61%
BlackRock, Inc.
356,675$179.2k-0.23%no data
0.59%
Dror Ben-Asher
346,062$173.9k0%no data
0.27%
Apo Asset Management GmbH
155,336$78.1k0%0.03%
0.25%
Morgan Stanley, Investment Banking and Brokerage Investments
144,222$72.5k268.7%no data
0.18%
Eric Swenden
106,309$53.4k0%no data
0.16%
Claret Asset Management Corp
95,430$48.0k0%0.01%
0.16%
Rick Scruggs
92,000$46.2k0%no data
0.14%
Ancora Advisors LLC
82,048$41.2k0%no data
0.12%
Creative Planning, LLC
67,601$34.0k0%no data
0.11%
Canadian Imperial Bank of Commerce, Asset Management Arm
65,575$33.0k0%no data
0.089%
State Street Global Advisors, Inc.
52,198$26.2k0.32%no data
0.087%
Barclays PLC Private Banking & Investment Banking Investment
51,000$25.6k-33.33%no data
0.087%
Kivun Trust Funds Management
50,885$25.6k0%0.07%
0.085%
Susquehanna International Group, LLP, Asset Management Arm
49,720$25.0k25.98%no data
0.084%
Group One Trading LP, Asset Management Arm
48,895$24.6k187.5%no data
0.075%
Annandale Capital, LLC
43,532$21.9k0%0.01%

Company Information

RedHill Biopharma Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: RedHill Biopharma Ltd.
  • Ticker: RDHL
  • Exchange: NasdaqGM
  • Founded: 2009
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$29.306m
  • Shares outstanding: 58.32m
  • Website: https://www.redhillbio.com

Number of Employees


Location

  • RedHill Biopharma Ltd.
  • 21 Ha’arba’a Street
  • Tel Aviv
  • 6473921
  • Israel


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RDHLNasdaqGM (Nasdaq Global Market)YesSPONSORED ADSUSUSDDec 2012
2RHDB (Deutsche Boerse AG)YesSPONSORED ADSDEEURDec 2012

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/02 00:00
End of Day Share Price2022/09/30 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.